Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy.

von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA.

Oncotarget. 2017 Oct 6;9(1):3-20. doi: 10.18632/oncotarget.21545. eCollection 2018 Jan 2.

2.

Emerging combination therapies for the management of multiple myeloma: the role of elotuzumab.

Chen WC, Kanate AS, Craig M, Petros WP, Hazlehurst LA.

Cancer Manag Res. 2017 Jul 12;9:307-314. doi: 10.2147/CMAR.S117477. eCollection 2017. Review.

3.

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.

Shay G, Tauro M, Loiodice F, Tortorella P, Sullivan DM, Hazlehurst LA, Lynch CC.

Oncotarget. 2017 Jun 27;8(26):41827-41840. doi: 10.18632/oncotarget.18103.

4.

MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.

Emmons MF, Anreddy N, Cuevas J, Steinberger K, Yang S, McLaughlin M, Silva A, Hazlehurst LA.

Sci Rep. 2017 Jun 2;7(1):2685. doi: 10.1038/s41598-017-02713-0.

5.

Stable and Potent Selenomab-Drug Conjugates.

Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR Jr, Rader C.

Cell Chem Biol. 2017 Apr 20;24(4):433-442.e6. doi: 10.1016/j.chembiol.2017.02.012. Epub 2017 Mar 16.

6.

High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor.

Geldenhuys WJ, Bergeron SA, Mullins JE, Aljammal R, Gaasch BL, Chen WC, Yun J, Hazlehurst LA.

Bioorg Med Chem Lett. 2017 May 1;27(9):2029-2037. doi: 10.1016/j.bmcl.2017.02.068. Epub 2017 Feb 28.

PMID:
28320616
7.

Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.

Anreddy N, Hazlehurst LA.

J Cell Biochem. 2017 Jan;118(1):15-25. doi: 10.1002/jcb.25617. Epub 2016 Jun 21. Review.

8.

Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Shay G, Hazlehurst L, Lynch CC.

J Mol Med (Berl). 2016 Jan;94(1):21-35. doi: 10.1007/s00109-015-1345-4. Epub 2015 Oct 1. Review.

9.

Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma.

Meads MB, Fang B, Mathews L, Gemmer J, Nong L, Rosado-Lopez I, Nguyen T, Ring JE, Matsui W, MacLeod AR, Pachter JA, Hazlehurst LA, Koomen JM, Shain KH.

Oncogene. 2016 May;35(21):2723-34. doi: 10.1038/onc.2015.334. Epub 2015 Sep 21.

10.

A preclinical assay for chemosensitivity in multiple myeloma.

Khin ZP, Ribeiro ML, Jacobson T, Hazlehurst L, Perez L, Baz R, Shain K, Silva AS.

Cancer Res. 2014 Jan 1;74(1):56-67. doi: 10.1158/0008-5472.CAN-13-2397. Epub 2013 Dec 5.

11.

CRM1 Inhibition Sensitizes Drug Resistant Human Myeloma Cells to Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex Vivo.

Turner JG, Dawson J, Emmons MF, Cubitt CL, Kauffman M, Shacham S, Hazlehurst LA, Sullivan DM.

J Cancer. 2013 Sep 10;4(8):614-25. doi: 10.7150/jca.7080. eCollection 2013.

12.

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.

Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.

Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18.

13.

The one-two punch: combination treatment in chronic myeloid leukemia.

Sweet KL, Hazlehurst LA, Pinilla-Ibarz J.

Crit Rev Oncol Hematol. 2013 Dec;88(3):667-79. doi: 10.1016/j.critrevonc.2013.07.017. Epub 2013 Aug 20. Review.

PMID:
23969231
14.

Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Schonbrunn E, Betzi S, Alam R, Martin MP, Becker A, Han H, Francis R, Chakrasali R, Jakkaraj S, Kazi A, Sebti SM, Cubitt CL, Gebhard AW, Hazlehurst LA, Tash JS, Georg GI.

J Med Chem. 2013 May 23;56(10):3768-82. doi: 10.1021/jm301234k. Epub 2013 May 6.

15.

Emerging strategies for targeting cell adhesion in multiple myeloma.

Nair RR, Gebhard AW, Emmons MF, Hazlehurst LA.

Adv Pharmacol. 2012;65:143-89. doi: 10.1016/B978-0-12-397927-8.00006-3. Review.

PMID:
22959026
16.

Role of STAT3 in Transformation and Drug Resistance in CML.

Nair RR, Tolentino JH, Hazlehurst LA.

Front Oncol. 2012 Apr 10;2:30. doi: 10.3389/fonc.2012.00030. eCollection 2012.

17.

Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML.

Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA.

Leuk Res. 2012 Jun;36(6):756-63. doi: 10.1016/j.leukres.2011.12.002. Epub 2011 Dec 30.

18.

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.

Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA.

Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6.

19.

Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Xiang Y, Remily-Wood ER, Oliveira V, Yarde D, He L, Cheng JQ, Mathews L, Boucher K, Cubitt C, Perez L, Gauthier TJ, Eschrich SA, Shain KH, Dalton WS, Hazlehurst L, Koomen JM.

Mol Cell Proteomics. 2011 Nov;10(11):M110.005520. doi: 10.1074/mcp.M110.005520. Epub 2011 Aug 16.

20.

A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer.

Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N, Kaufman LM, Ochoa JE, Hazlehurst L, Pinilla-Ibarz J, Lancet J, Zhang G, Haura E, Shibata D, Yeatman T, Smalley KS, Dalton WS, Huang E, Scott E, Bloom GC, Eschrich SA, Koomen JM.

Proteomics Clin Appl. 2011 Aug;5(7-8):383-96. doi: 10.1002/prca.201000115. Epub 2011 Jun 8.

21.

Tipifarnib-induced apoptosis in acute myeloid leukemia and multiple myeloma cells depends on Ca2+ influx through plasma membrane Ca2+ channels.

Yanamandra N, Buzzeo RW, Gabriel M, Hazlehurst LA, Mari Y, Beaupre DM, Cuevas J.

J Pharmacol Exp Ther. 2011 Jun;337(3):636-43. doi: 10.1124/jpet.110.172809. Epub 2011 Mar 4.

22.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Nair RR, Tolentino J, Hazlehurst LA.

Biochem Pharmacol. 2010 Sep 1;80(5):602-12. doi: 10.1016/j.bcp.2010.04.003. Epub 2010 Apr 9. Review.

23.

Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.

Yarde DN, Oliveira V, Mathews L, Wang X, Villagra A, Boulware D, Shain KH, Hazlehurst LA, Alsina M, Chen DT, Beg AA, Dalton WS.

Cancer Res. 2009 Dec 15;69(24):9367-75. doi: 10.1158/0008-5472.CAN-09-2616.

24.

Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.

Turner JG, Marchion DC, Dawson JL, Emmons MF, Hazlehurst LA, Washausen P, Sullivan DM.

Cancer Res. 2009 Sep 1;69(17):6899-905. doi: 10.1158/0008-5472.CAN-09-0484. Epub 2009 Aug 18.

25.

HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells.

Nair RR, Emmons MF, Cress AE, Argilagos RF, Lam K, Kerr WT, Wang HG, Dalton WS, Hazlehurst LA.

Mol Cancer Ther. 2009 Aug;8(8):2441-51. doi: 10.1158/1535-7163.MCT-09-0113. Epub 2009 Aug 11.

26.

Detection of DNA damage induced by topoisomerase II inhibitors, gamma radiation and crosslinking agents using the comet assay.

Hazlehurst LA.

Methods Mol Biol. 2009;523:169-76. doi: 10.1007/978-1-59745-190-1_12.

PMID:
19381939
27.

Signaling networks associated with BCR-ABL-dependent transformation.

Hazlehurst LA, Bewry NN, Nair RR, Pinilla-Ibarz J.

Cancer Control. 2009 Apr;16(2):100-7. Review.

PMID:
19337196
28.

Towards a framework for analysis of biophotonic images of mouse models of cancer.

Kamath V, Goldgof D, Argilagos R, Hazlehurst L, Eschrich S.

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:3079-82. doi: 10.1109/IEMBS.2008.4649854.

PMID:
19163357
29.

Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation.

Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA, Dalton WS.

Cancer Res. 2009 Feb 1;69(3):1009-15. doi: 10.1158/0008-5472.CAN-08-2419. Epub 2009 Jan 20.

30.

Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.

Bewry NN, Nair RR, Emmons MF, Boulware D, Pinilla-Ibarz J, Hazlehurst LA.

Mol Cancer Ther. 2008 Oct;7(10):3169-75. doi: 10.1158/1535-7163.MCT-08-0314.

31.

Proteomic contributions to personalized cancer care.

Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS.

Mol Cell Proteomics. 2008 Oct;7(10):1780-94. doi: 10.1074/mcp.R800002-MCP200. Epub 2008 Jul 29. Review.

32.

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance.

Meads MB, Hazlehurst LA, Dalton WS.

Clin Cancer Res. 2008 May 1;14(9):2519-26. doi: 10.1158/1078-0432.CCR-07-2223. Review.

33.

Cell adhesion induces p27Kip1-associated cell-cycle arrest through down-regulation of the SCFSkp2 ubiquitin ligase pathway in mantle-cell and other non-Hodgkin B-cell lymphomas.

Lwin T, Hazlehurst LA, Dessureault S, Lai R, Bai W, Sotomayor E, Moscinski LC, Dalton WS, Tao J.

Blood. 2007 Sep 1;110(5):1631-8. Epub 2007 May 14.

34.

Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells.

Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC, Dalton WS, Tao J.

Leukemia. 2007 Jul;21(7):1521-31. Epub 2007 May 3.

PMID:
17476277
35.

Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.

Hazlehurst LA, Argilagos RF, Dalton WS.

Br J Haematol. 2007 Jan;136(2):269-75.

PMID:
17233818
36.

ABCG2 expression, function, and promoter methylation in human multiple myeloma.

Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS, Sullivan DM.

Blood. 2006 Dec 1;108(12):3881-9. Epub 2006 Aug 17.

37.

Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.

Emmons M, Boulware D, Sullivan DM, Hazlehurst LA.

Biochem Pharmacol. 2006 Jun 28;72(1):11-8. Epub 2006 Mar 28.

PMID:
16678798
38.

Cell adhesion to fibronectin (CAM-DR) influences acquired mitoxantrone resistance in U937 cells.

Hazlehurst LA, Argilagos RF, Emmons M, Boulware D, Beam CA, Sullivan DM, Dalton WS.

Cancer Res. 2006 Feb 15;66(4):2338-45.

39.

The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.

Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS.

Blood. 2005 Jul 15;106(2):698-705. Epub 2005 Mar 31.

40.

Targeting the bone marrow microenvironment in hematologic malignancies.

Dalton WS, Hazlehurst L, Shain K, Landowski T, Alsina M.

Semin Hematol. 2004 Apr;41(2 Suppl 4):1-5. Review.

PMID:
15190509
41.

The cytoplasmic trafficking of DNA topoisomerase IIalpha correlates with etoposide resistance in human myeloma cells.

Engel R, Valkov NI, Gump JL, Hazlehurst L, Dalton WS, Sullivan DM.

Exp Cell Res. 2004 May 1;295(2):421-31.

PMID:
15093741
42.

Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.

Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.

Cancer Res. 2003 Nov 15;63(22):7900-6.

43.

Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death.

Hazlehurst LA, Landowski TH, Dalton WS.

Oncogene. 2003 Oct 20;22(47):7396-402. Review.

PMID:
14576847
44.

Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies.

Hazlehurst LA, Dalton WS.

Cancer Metastasis Rev. 2001;20(1-2):43-50. Review.

PMID:
11831646
45.

Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.

Oshiro MM, Landowski TH, Catlett-Falcone R, Hazlehurst LA, Huang M, Jove R, Dalton WS.

Clin Cancer Res. 2001 Dec;7(12):4262-71.

46.

Multiple Myeloma: New Insights and Therapeutic Approaches.

Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J.

Hematology Am Soc Hematol Educ Program. 2000:147-165.

PMID:
11701540
47.

Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.

Hazlehurst LA, Valkov N, Wisner L, Storey JA, Boulware D, Sullivan DM, Dalton WS.

Blood. 2001 Sep 15;98(6):1897-903.

49.

Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR).

Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS.

Oncogene. 2000 Sep 7;19(38):4319-27.

50.

Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.

Hazlehurst LA, Foley NE, Gleason-Guzman MC, Hacker MP, Cress AE, Greenberger LW, De Jong MC, Dalton WS.

Cancer Res. 1999 Mar 1;59(5):1021-8.

Supplemental Content

Loading ...
Support Center